![](/img/cover-not-exists.png)
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
Schuler, Martin, Paz-Ares, Luis, Sequist, Lecia V., Hirsh, Vera, Lee, Ki Hyeong, Wu, Yi-Long, Lu, Shun, Zhou, Caicun, Feng, Jifeng, Ellis, Stuart H., Samuelsen, Carl H., Tang, Wenbo, Märten, Angela, EJournal:
Lung Cancer
DOI:
10.1016/j.lungcan.2019.04.006
Date:
April, 2019
File:
PDF, 639 KB
2019